Digoxin

Generic Name: Digoxin

Brand Names: Digox, Lanoxin

Drug Type: Small Molecule

Chemical Formula: C_₄₁H_₆₄O_₁₄

CAS Number: 20830-75-5

Unique Ingredient Identifier: 73K4184T59

Background: Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...

Indication: Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...

Associated Conditions: Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure

Associated Therapies: -

Clinical Trials

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin
Drug: Caffeine
Drug: Rosuvastatin
Drug: Atorvastatin
Drug: Simvastatin

First Posted Date: 2016-02-18

Last Posted Date: 2017-11-24

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 36

Registration Number: NCT02685462

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ITCA 650 20/60 mcg/day
Drug: Acetaminophen
Drug: Atorvastatin
Drug: Lisinopril
Drug: Warfarin
Drug: Digoxin

First Posted Date: 2015-12-30

Last Posted Date: 2017-01-27

Lead Sponsor: Intarcia Therapeutics

Target Recruit Count: 33

Registration Number: NCT02641899

Locations: 🇺🇸
Quintiles, Overland Park, Kansas, United States

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

Phase 1

Completed

Conditions: cMET-dysregulated Advanced Solid Tumors

Interventions: Drug: INC280
Drug: digoxin
Drug: rosuvastatin

First Posted Date: 2015-12-10

Last Posted Date: 2020-12-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT02626234

Locations: 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
🇺🇸
Emory University School of Medicine/Winship Cancer Institute Phase 1 Working Group, Atlanta, Georgia, United States

Digoxin Short Term Treatment Assessment Randomized Trial in AHF

Phase 3

Recruiting

Conditions: Acute Heart Failure

Interventions: Drug: Digoxin
Drug: Placebo

First Posted Date: 2015-09-09

Last Posted Date: 2023-12-18

Lead Sponsor: University of Monastir

Target Recruit Count: 500

Registration Number: NCT02544815

Locations: 🇹🇳
Fattouma Bourguiba University Hospital, Monastir, Tunisia
🇹🇳
Sahloul University Hospital, Hammam sousse, Sousse, Tunisia

Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PEX168
Drug: Digoxin

First Posted Date: 2015-06-15

Last Posted Date: 2017-01-24

Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT02472236

Locations: 🇨🇳
The first affiliate of Xi'an Jiaotong University, Xi'an, Shanxi, China

The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin
Drug: PEX168

First Posted Date: 2015-05-22

Last Posted Date: 2016-11-30

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 16

Registration Number: NCT02451527

Locations: 🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xian, Shaanxi, China

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

Phase 1

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Rolapitant
Drug: Cooperstown Cocktail
Drug: Digoxin
Drug: Sulfasalazine

First Posted Date: 2015-05-05

Last Posted Date: 2015-08-25

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 102

Registration Number: NCT02434861

Locations: 🇺🇸
Parexel Early Phase Unit, Baltimor, Maryland, United States

Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)

Phase 4

Completed

Conditions: Permanent Atrial Fibrillation

Interventions: Drug: Bisoprolol
Drug: Digoxin

First Posted Date: 2015-03-18

Last Posted Date: 2021-06-18

Lead Sponsor: University of Birmingham

Target Recruit Count: 161

Registration Number: NCT02391337

Locations: 🇬🇧
Queen Elizabeth Hospital, Birmingham, West Midlands, United Kingdom
🇬🇧
City Hospital, Birmingham, West Midlands, United Kingdom

Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam

Phase 1

Completed

Conditions: Japanese Healthy Adult Males

Interventions: Drug: TAK-272
Drug: Itraconazole
Drug: Digoxin
Drug: Midazolam

First Posted Date: 2015-02-25

Last Posted Date: 2016-05-23

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT02370615

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Omeprazole
Drug: Midazolam
Drug: Warfarin
Drug: Digoxin
Drug: BI 1181181

First Posted Date: 2015-01-26

Last Posted Date: 2015-03-10

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02345304

Locations: 🇩🇪
1344.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy